Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
PCYC [NASD]
Pharmacyclics Inc.
Index- P/E119.59 EPS (ttm)0.79 Insider Own16.30% Shs Outstand75.03M Perf Week4.93%
Market Cap7.09B Forward P/E147.63 EPS next Y0.64 Insider Trans-0.30% Shs Float60.68M Perf Month-14.67%
Income67.00M PEG747.47 EPS next Q0.20 Inst Own66.90% Short Float4.22% Perf Quarter-32.85%
Sales260.20M P/S27.24 EPS this Y-45.30% Inst Trans1.10% Short Ratio1.88 Perf Half Y-27.10%
Book/sh8.49 P/B11.13 EPS next Y2233.30% ROA10.60% Target Price164.44 Perf Year17.61%
Cash/sh8.47 P/C11.15 EPS next 5Y0.16% ROE13.00% 52W Range74.36 - 154.89 Perf YTD-10.68%
Dividend- P/FCF100.69 EPS past 5Y24.50% ROI10.70% 52W High-39.00% Beta0.78
Dividend %- Quick Ratio8.30 Sales past 5Y- Gross Margin- 52W Low27.06% ATR6.00
Employees484 Current Ratio8.50 Sales Q/Q113.10% Oper. Margin37.60% RSI (14)36.57 Volatility4.68% 6.58%
OptionableYes Debt/Eq0.00 EPS Q/Q43.90% Profit Margin25.70% Rel Volume0.99 Prev Close93.61
ShortableYes LT Debt/Eq0.00 EarningsApr 28 Payout0.00% Avg Volume1.37M Price94.48
Recom2.10 SMA20-2.83% SMA50-20.58% SMA200-20.93% Volume1,351,645 Change0.93%
21-Feb-14Reiterated Deutsche Bank Buy $170 → $180
18-Dec-13Initiated WallachBeth Hold $108
26-Sep-13Initiated Deutsche Bank Buy $170
12-Dec-12Reiterated Wedbush Outperform $93 → $110
24-Aug-12Initiated Stifel Nicolaus Hold
02-Aug-12Downgrade Needham Buy → Hold
17-May-12Reiterated Rodman & Renshaw Mkt Outperform $22 → $40
17-May-12Reiterated Needham Buy $23 → $32
21-Feb-12Upgrade RBC Capital Mkts Sector Perform → Outperform $15 → $34
09-Dec-11Downgrade RBC Capital Mkts Outperform → Sector Perform $15 → $15
09-Dec-11Downgrade Global Hunter Securities Buy → Neutral $15 → $15
07-Dec-11Initiated Rodman & Renshaw Mkt Outperform $20
11-Nov-11Resumed Needham Buy $14
20-Jun-11Reiterated RBC Capital Mkts Outperform $10 → $15
07-Jun-10Reiterated Wedbush Outperform $8 → $16
14-Apr-10Reiterated Roth Capital Buy $7 → $11
12-Mar-10Initiated Roth Capital Buy $7
12-Feb-10Downgrade BWS Financial Buy → Hold
29-Jan-10Initiated Merriman Buy
17-Feb-09Reiterated RBC Capital Mkts Outperform $4 → $2
22-Apr-14 09:32AM  Why Johnson & Johnson Is Outperforming the Dow at Motley Fool
21-Apr-14 04:47PM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
11:45AM  Pharmacyclics Announces Presentation of Phase III and Long Term Follow Up Data on IMBRUVICA in Chronic Lymphocytic Leukemia (CLL) at ASCO PR Newswire
17-Apr-14 08:48AM  The Zacks Analyst Blog Highlights: GIlead, AbbVie, MannKind, Alkermes and Pharmacyclics Zacks
04:41AM  Cramer's Lightning Round - Gigamon Is In The Penalty Box (4/16/14) at Seeking Alpha
16-Apr-14 06:47PM  Lightning Round: Southwest Airlines, Blackstone & More at CNBC
06:30AM  A Lucky Drug Made Pharmacyclics' Robert Duggan A Billionaire. Will Long-Term Success Follow? at Forbes
15-Apr-14 12:23PM  The Recent Performance of 'Baker Brother Biotech Stocks' is Awful at TheStreet
10:06AM  J&J beats forecasts, helped by new medicines at CNBC
09-Apr-14 10:30AM  Pharmacyclics Files sNDA Zacks
08-Apr-14 04:11PM  PHARMACYCLICS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
01:13PM  Is biotech caught in a bubble, and is it popping? at MarketWatch
12:25PM  PHARMACYCLICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
09:23AM  Todays Top Biotech Stories: Takeda, Eli Lilly, Immunomedics, and Pharmacyclics at Motley Fool
08:00AM  Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with Phase III CLL Study Data PR Newswire
28-Mar-14 04:58PM  3 Biotech Stocks Trading The Wrong Direction In March at Seeking Alpha
08:35AM  Credit Suisse Sees These Six Stocks as Momentum Traps 24/7 Wall St.
27-Mar-14 05:43PM  Is It Time to Buy These 2 Cancer-Fighting Companies? at Motley Fool
08:56AM  PHARMACYCLICS INC Files SEC form 8-K, Other Events EDGAR Online
08:55AM  Morgan Stanley Starts Mixed Coverage on Top Biotech Stocks at 24/7 Wall St.
21-Mar-14 06:00AM  'Mad Money' Lightning Round: VMware Is the One to Own at TheStreet
20-Mar-14 11:25AM  Pharmacyclics Drug Imbruvica Beats Rivals: Nomura at Investor's Business Daily
11-Mar-14 04:47PM  Gilead Sciences' Novel Leukemia Drug Should Extend Company Profits at Seeking Alpha
09:00AM  BioClinica Technology Supports Pharmacyclics in Achieving Early Approval of IMBRUVICA and Breakthrough Therapy Designations for Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) PR Newswire
09-Mar-14 05:05AM  Pharmacyclics: 7 Different Insiders Have Sold Shares During The Last 30 Days at Seeking Alpha
05:05AM  Pharmacyclics: 7 Different Insiders Have Sold Shares During The Last 30 Days
05-Mar-14 05:38PM  WuXi Pharma Q4 Earnings Topt, But Q1 Guidance Misses at Investor's Business Daily
05:38PM  WuXi Pharma Q4 Earnings Top, But Q1 Guidance Misses Optionetics
05:38PM  WuXi Pharma Q4 Earnings Top, But Q1 Guidance Misses at Investor's Business Daily
05:38PM  WuXi Pharma Q4 Earnings Top, But Q1 Guidance Misses
04-Mar-14 01:04PM  PHARMACYCLICS INC Financials EDGAR Online Financials
08:49AM  PHARMACYCLICS INC Files SEC form 8-K, Other Events EDGAR Online
27-Feb-14 06:31PM  Can Pharmacyclics, Inc.'s Imbruvica Stay Ahead of Gilead Sciences, Inc.'s Idelalisib? at Motley Fool
26-Feb-14 05:13PM  PHARMACYCLICS INC Files SEC form 10-K, Annual Report EDGAR Online
25-Feb-14 02:31PM  1 Drug Critical to Johnson & Johnson's Future Success at Motley Fool
01:54PM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
24-Feb-14 04:00PM  Pharmacyclics Attains 52-Week High Zacks
04:00PM  Pharmacyclics Attains 52-Week High
09:16AM  JMPs King Recommends Shares of Pharmacyclics (Audio) at Bloomberg
06:02AM  Surging Earnings Estimates Signal Good News for Pharmacyclics (PCYC) Zacks
21-Feb-14 02:37PM  Is Gilead About to Become an Oncology Powerhouse? at Motley Fool +6.26%
12:31PM  Pharmacyclics Hits High As Imbruvica Launches Big at Investor's Business Daily
11:10AM  Pharmacyclics Beats on Earnings, Revenues in Q4 Zacks
09:00AM  Pharmacyclics price target raised to $191 from $163 at JMP Securities at theflyonthewall.com
20-Feb-14 11:50PM  Pharmacyclics Management Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
04:25PM  Pharmacyclics, Inc. Discusses Q4 2013 Results (Webcast) at Seeking Alpha
04:07PM  PHARMACYCLICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit EDGAR Online
04:03PM  Who Is Responsible For Biotech's Torrid Start to 2014? at TheStreet
04:01PM  Pharmacyclics Reports Fourth Quarter and Full Year 2013 Results PR Newswire
07:07AM  Q4 2014 Pharmacyclics Earnings Release - After Market Close CCBN
14-Feb-14 03:45PM  Pharmacyclics Announces Date of Conference call to discuss Financial Results for Fourth Quarter and Year End 2013 PR Newswire
08:11AM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
13-Feb-14 03:30PM  Pharmacyclics Gains on Imbruvica Label Expansion Zacks
12-Feb-14 06:43PM  Pharmacyclics up on FDA OK Investor's Business Daily
02:52PM  FDA clears Pharmacyclics drug for new cancer use AP
02:05PM  Pharmacyclics' Imbruvica Wins Second Cancer Approval at Investor's Business Daily
02:04PM  PHARMACYCLICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
01:57PM  FDA approval of leukemia treatment boosts shares of Pharmacyclics at MarketWatch
01:52PM  FDA clears Pharmacyclics drug for new cancer use AP
01:18PM  U.S. Food and Drug Administration Approves IMBRUVICA (ibrutinib) as a Single Agent for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy PR Newswire
12:55PM  Pharmacyclics, J&J Win Wider Use of Blood Cancer Drug at Bloomberg
07-Feb-14 02:22PM  Ram Selvaraju: A Pair Of Companies Ride The Sea Change In Cancer Therapeutics at Seeking Alpha
05-Feb-14 04:16PM  PHARMACYCLICS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
03-Feb-14 03:20PM  Pharmacyclics: Facts Behind $10B Market Cap at Seeking Alpha
28-Jan-14 06:29PM  A $10 Billion Market By 2022: Pharmacyclic's Piece Of It at Seeking Alpha
06:29PM  A $10 Billion Market By 2022: Pharmacyclic's Piece Of It
24-Jan-14 07:50AM  Can the Rally in Pharmacyclics (PCYC) Shares Continue? Zacks
07:50AM  Can the Rally in Pharmacyclics (PCYC) Shares Continue?
15-Jan-14 12:06PM  JPMorgan Healthcare Conference Highlights: Pharmacyclics, Inc. at Motley Fool
12:06PM  JPMorgan Healthcare Conference Highlights: Pharmacyclics, Inc.
13-Jan-14 02:31PM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
02:31PM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure
11-Jan-14 11:46AM  This Week in Biotech: Putting on a Clinic at Motley Fool
11:46AM  This Week in Biotech: Putting on a Clinic
09-Jan-14 02:16PM  Why Pharmacyclics and J&J's Lack of Data Is So Amazing at Motley Fool
02:16PM  Why Pharmacyclics and J&J's Lack of Data Is So Amazing
01:43PM  Biotech Bull Market: 2014 Key Trends To Watch at Seeking Alpha
07-Jan-14 08:02PM  Why Pharmacyclics, Valeant Pharmaceuticals, and Cray Jumped Today at Motley Fool +19.84%
08:02PM  Why Pharmacyclics, Valeant Pharmaceuticals, and Cray Jumped Today
07:36PM  Pharmacyclics Inc. Crushes Critical Trial at Motley Fool
07:36PM  Pharmacyclics Inc. Crushes Critical Trial
06:45PM  Valeant Dreams Big; Cancer Drug News Lifts Pharmacyclics Investor's Business Daily
06:45PM  Valeant Dreams Big; Cancer Drug News Lifts Pharmacyclics
06:00PM  [video] Bull rally still have room to run? at CNBC
06:00PM  [video] Bull rally still have room to run?
05:16PM  PHARMACYCLICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
05:16PM  PHARMACYCLICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:22PM  On The Fly: Closing Wrap at theflyonthewall.com
03:43PM  Why Pharmacyclics Inc. Shares Vaulted Higher at Motley Fool
03:43PM  Why Pharmacyclics Inc. Shares Vaulted Higher
01:20PM  Nasdaq stocks posting largest percentage increases AP
12:49PM  Midday movers: Herbalife, Eli Lilly, Cray & More at CNBC
12:29PM  Pharmacyclics Scores an Early Phase 3 Victory at Wall St. Cheat Sheet
12:29PM  Pharmacyclics Scores an Early Phase 3 Victory
12:09PM  Pharmacyclics shares soar after panel says cancer drug met goals at MarketWatch
12:09PM  Pharmacyclics shares soar after panel says cancer drug met goals
11:26AM  Pharmacyclics Drug Trial To End Early On Strong Data at Investor's Business Daily
11:23AM  Wall Street Expects Pharmacyclics Drug's Positive Result To Lead To Off-Label Prescribing at Forbes
11:08AM  Pharmacyclics Shares Rise on Positive Leukemia Trial at Bloomberg
10:50AM  Pharmacyclics data has positive read through to FDA decision, says Credit Suisse at theflyonthewall.com
Pharmacyclics, Inc., a biopharmaceutical company, designs, develops, and commercializes small-molecule drugs for the treatment of cancer and immune mediated diseases in the United States and internationally. The company offers IMBRUVICATM as a single agent for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy. Its products candidate in clinical development includes IMBRUVICA BTK inhibitor, which is under multiple Phase I, II, III clinical trials for the treatment of naive and relapsed/refractory chronic lymphocytic leukemia, naive and relapsed/refractory diffuse large B-cell lymphoma, naive follicular lymphoma, relapsed/refractory mantle cell lymphoma, relapsed/refractory follicular lymphoma, relapsed/refractory multiple myeloma, Waldenstrom's macroglobulinemia, and relapsed/refractory marginal zone lymphoma. The company is also developing a BTK inhibitor lead optimization program, which is in Phase I clinical trials targeting anti-inflammatory and autoimmune indications; PCI-27483, an inhibitor of Factor VIIa that is in multiple Phase I, II clinical trials for the treatment of cancer; and PCI-24781, a HDAC inhibitor abexinostat, which is in multiple Phase I, II clinical trials for the treatment of relapsed/refractory lymphomas and solid tumors. The company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. It has a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize ibrutinib and related compounds; collaboration and license agreement with Les Laboratoires Servier to develop and commercialize abexinostat; and license agreement with Novo Nordisk A/S to research and develop PCI-27483. Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fardis MariaChief of Oncology Ops & AllianMar 05Option Exercise6.843,00020,5205,988Mar 07 06:06 PM
McGreivy JesseChief Medical OfficerMar 05Option Exercise25.336,563166,2416,563Mar 06 04:35 PM
Hemmi GregorySr. VP Chemical OperationsMar 05Option Exercise0.8615,00012,90053,004Mar 06 06:06 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 05Option Exercise25.946,253162,2037,992Mar 06 04:33 PM
Hemmi GregorySr. VP Chemical OperationsMar 05Sale140.0015,0002,100,03338,004Mar 06 06:06 PM
Fardis MariaChief of Oncology Ops & AllianMar 05Sale140.503,000421,5042,988Mar 07 06:06 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 05Sale140.756,253880,1151,739Mar 06 04:33 PM
McGreivy JesseChief Medical OfficerMar 05Sale139.666,563916,5990Mar 06 04:35 PM
Chang Betty YVP, Research/BiologyMar 04Option Exercise10.2417,500179,23821,254Mar 05 08:15 PM
HALVORSON ERIC HDirectorMar 04Option Exercise17.663,47261,3324,472Mar 06 02:46 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 04Option Exercise25.9413,747356,59715,486Mar 06 04:33 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 04Sale137.0713,7471,884,3301,739Mar 06 04:33 PM
HALVORSON ERIC HDirectorMar 04Sale138.333,472480,2821,000Mar 06 02:46 PM
Chang Betty YVP, Research/BiologyMar 04Sale137.9717,5002,414,4843,754Mar 05 08:15 PM
van den Broek RichardDirectorFeb 27Sale144.9225,0003,622,99029,610Feb 28 05:26 PM
van den Broek RichardDirectorFeb 26Sale147.1325,6803,778,17054,610Feb 28 05:26 PM
van den Broek RichardDirectorFeb 25Sale147.7028,1554,158,49680,290Feb 28 05:26 PM
Hemmi GregoryVP Chemical OperationsDec 30Option Exercise0.7513,0009,75038,004Jan 02 01:15 PM
Tan HeowChief Quality&Tech OperationsDec 24Option Exercise27.051,50040,5751,669Dec 26 06:10 PM
Smith David DuaneDirectorDec 20Option Exercise1.921,0001,9203,000Dec 20 05:22 PM
Tan HeowChief Quality&Tech OperationsDec 19Option Exercise27.055,000135,2505,169Dec 20 02:44 PM
Tan HeowChief Quality&Tech OperationsDec 19Sale100.875,000504,352169Dec 20 02:44 PM
Hemmi GregoryVP Chemical OperationsDec 18Option Exercise0.8610,0008,60035,004Dec 18 07:30 PM
Hemmi GregoryVP Chemical OperationsDec 18Sale99.0410,000990,38025,004Dec 18 07:30 PM
Hemmi GregoryVP Chemical OperationsDec 17Option Exercise0.8610,0008,60035,004Dec 18 07:30 PM
Hemmi GregoryVP Chemical OperationsDec 17Sale102.0010,0001,020,00025,004Dec 18 07:30 PM
Erdtmann Rainer MSr. VP, IR and AdminDec 16Option Exercise0.9122,83520,78034,332Dec 16 07:13 PM
Smith David DuaneDirectorDec 16Option Exercise1.926,50012,4808,500Dec 17 04:16 PM
Erdtmann Rainer MSr. VP, IR and AdminDec 16Sale107.7222,8352,459,68111,497Dec 16 07:13 PM
Zanganeh MakyChief Operating OfficerDec 16Sale107.5520,0002,151,000210,107Dec 18 07:24 PM
Erdtmann Rainer MSr. VP, IR and AdminDec 13Option Exercise0.9131,16528,36042,662Dec 16 07:13 PM
Erdtmann Rainer MSr. VP, IR and AdminDec 13Sale107.8231,1653,360,11411,497Dec 16 07:13 PM
Shearer Scott TVP, Global QualityJun 06Option Exercise30.4618,750571,12518,750Jun 06 06:46 PM
Shearer Scott TVP, Global QualityJun 06Sale85.1718,7501,596,9940Jun 06 06:46 PM
McGreivy JesseVP, Clinical ScienceMay 31Option Exercise37.8614,479548,10314,479May 31 08:02 PM
Love Richard BVP and General CounselMay 31Option Exercise32.388,000259,0408,000May 31 08:03 PM
Tan HeowChief of Technical OperationsMay 31Option Exercise27.055,000135,2505,237May 31 08:06 PM
Hemmi GregoryVP Chemical OperationsMay 31Option Exercise2.7050,000135,17974,236May 31 08:15 PM
Hemmi GregoryVP Chemical OperationsMay 31Sale91.9650,0004,598,11524,236May 31 08:15 PM
Tan HeowChief of Technical OperationsMay 31Sale91.845,237480,9610May 31 08:06 PM
Love Richard BVP and General CounselMay 31Sale89.008,000712,0000May 31 08:03 PM
McGreivy JesseVP, Clinical ScienceMay 31Sale91.1314,4791,319,5100May 31 08:02 PM